Pharma Industry News

Five-year Zolgensma data shows SMA benefit

If left untreated, SMA type I leads to death or the need for permanent ventilation by the age of two in more than 90% of cases.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]